Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 8/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 10/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5252318 | 0.86 | HTR6 (0.46) | HTR6DRD3HRH3HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL10395804 | 0.85 | HTR6 (0.46) | HTR6DRD3HRH3HTR2AHTR2C | |
| SCHEMBL9778470 | 0.80 | HTR6 (0.48) | CNR1HTR6HTR2A | |
| SCHEMBL5253368 | 0.80 | HTR6 (0.50) | HTR6DRD3HRH3HTR2AHTR2C | |
| SCHEMBL7483878 | 0.77 | HTR6 (0.67) | CYP3A4CYP2D6HTR6HTR2AHTR2C | |
| SCHEMBL5256131 | 0.76 | HTR6 (0.50) | CNR1HTR6HTR2A | |
| SCHEMBL18548054 | 0.76 | CNR1 (0.53) | CNR1 | |
| SCHEMBL18548003 | 0.74 | CNR1 (0.51) | CNR1HTR6 | |
| SCHEMBL5255255 | 0.74 | HTR6 (0.52) | HTR6HTR2AHTR2C | |
| SCHEMBL9778459 | 0.73 | MAT2A (0.56) | HTR6HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355904-B1 | HETEROCYCLINDAZOLE AND AZAINDAZOLE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH CORP (US) | 2007-08-01 | — | — | EP | claimed |
| EP-1803720-A1 | Heterocyclindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | Wyeth a Corporation of the State of Delaware (US) | 2007-07-04 | — | — | EP | claimed |
| CN-1553910-A | Heterocyclyl-indazole or azaindazole compounds as 5-hydroxytryptamine-6 ligands | — | 2004-12-08 | — | — | CN | claimed |
| US-20040092526-A1 | Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | WYETH | 2004-05-13 | — | — | US | claimed |
| EP-1355904-A2 | HETEROCYCLINDAZOLE AND AZAINDAZOLE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2003-10-29 | — | — | EP | claimed |
| US-20020198213-A1 | Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | AMERICAN HOME PRODUCTS CORPORATION | 2002-12-26 | — | — | US | claimed |
| WO-2002051837-A2 | HETEROCYCLINDAZOLE AND AZAINDAZOLE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2002-07-04 | — | — | WO | claimed |
| EP-1355904-B1 | HETEROCYCLINDAZOLE AND AZAINDAZOLE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH CORP (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1803720-A1 | Heterocyclindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | Wyeth a Corporation of the State of Delaware (US) | 2007-07-04 | — | — | EP | disclosed |
| CN-1281605-C | Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | WYETH CORP (US) | 2006-10-25 | — | — | CN | disclosed |
| US-20050124603-A1 | Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-06-09 | — | — | US | disclosed |
| US-6903112-B2 | Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-06-07 | — | — | US | disclosed |
| CN-1553910-A | Heterocyclyl-indazole or azaindazole compounds as 5-hydroxytryptamine-6 ligands | — | 2004-12-08 | — | — | CN | disclosed |
| US-6767912-B2 | SUCH AS 1-(PHENYLSULFONYL)-3-(PIPERIDIN-4-YL)-1H-INDAZOLE; FOR MOOD, MOTOR, OR COGNITIVE DISORDERS INCLUDING SCHIZOPHRENIA, ANXIETY, AND DEPRESSION | WYETH | 2004-07-27 | — | — | US | disclosed |
| US-20040092526-A1 | Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | WYETH | 2004-05-13 | — | — | US | disclosed |
| EP-1355904-A2 | HETEROCYCLINDAZOLE AND AZAINDAZOLE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20020198213-A1 | Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | AMERICAN HOME PRODUCTS CORPORATION | 2002-12-26 | — | — | US | disclosed |
| WO-2002051837-A2 | HETEROCYCLINDAZOLE AND AZAINDAZOLE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092526-A1 | Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1A | CNR1 34/4885CYP3A4 317/4885CYP2D6 69/4885 |
| US-20050124603-A1 | Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR3B | CNR1 39/4885CYP3A4 288/4885CYP2D6 61/4885 |
| US-20020198213-A1 | Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1A | CNR1 34/4885CYP3A4 317/4885CYP2D6 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.